Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes.
Metabolic syndrome, diabetes and diabetes complications pose a growing medical challenge worldwide, accentuating the need of safe and effective strategies for their clinical management. Here we present preclinical evidence that the sorbitol derivative meglumine (N-methyl-D-glucamine) can safely prot...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
Public Library of Science (PLoS)
2014-01-01
|
| Colección: | PLoS ONE |
| Acceso en línea: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090031&type=printable |